RxDoctor Payments Data

Curtis Matthews, MD

Urology · Rock Hill, SCNPI 1992879571

Payments from drug & device makers

$1,114in general payments, 2019–2025

Across 43 payments — averaging $25.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nevro Corp.$306
  • Astellas Pharma US Inc$302
  • C. R. Bard, Inc. & Subsidiaries$210
  • Boston Scientific$88
  • Aytu Biopharma, Inc.$52
  • Ferring Pharmaceuticals Inc.$49
  • plus $107 from 7 others

What the payments were for

  • Food & beverage$1,06295%
  • Education$525%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,114 in reported general payments places this provider in the 30th percentile of 196 urology providers in South Carolina.

See all urology providers in South Carolina

Medicare billing

Part B allowed, 2024
$172,622
Medicare patients
515
Services billed
3,713

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron103$67,310
Methenamine Hippurate102$9,412
GemtesaVibegron19$9,160
Trospium Chloride ErTrospium Chloride16$5,168
Tamsulosin Hcl327$4,456
Silodosin42$3,330
Solifenacin Succinate48$3,028
Dutasteride58$2,302
Testosterone Cypionate38$1,815
Trimethoprim15$1,524
Finasteride114$1,443
Potassium Citrate ErPotassium Citrate17$1,371
NitrofurantoinNitrofurantoin Macrocrystal19$1,053
Alfuzosin Hcl ErAlfuzosin Hcl46$997
Tolterodine Tartrate ErTolterodine Tartrate14$783

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$302$67,310103 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 196 urology providers in South Carolina.

Other urology in Rock Hill

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →